Avalo Therapeutics
AVTX
12 hedge funds and large institutions have $209K invested in Avalo Therapeutics in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 16 closing their positions.
32% more capital invested
Capital invested by funds: $159K → $209K (+$50.4K)
0.01% less ownership
Funds ownership: 0.03% → 0.01% (-0.01%)
50% less funds holding
Funds holding: 24 → 12 (-12)
75% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$348K |
| 2 |
N
Natixis
Paris,
France
|
+$104K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$35.1K |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$11.8K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$34K |
| 2 |
VF
Virtu Financial
New York
|
-$22K |
| 3 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$19.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$16.1K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$11.1K |
AVTX Hedge Fund Activity: Q4 2023 in Review
12 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2023, worth a combined $209K — up 32% from $159K a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AVTX and 4 opened new positions — a net loss of 12 holders — while 0 trimmed existing stakes and 5 added.
The largest buyer was BlackRock, adding an estimated $348K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $34K sold.
- 12 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2023, down from 24 in Q3 2023.
- Funds reported $209K of Avalo Therapeutics stock for Q4 2023, up 32% quarter-over-quarter.
- 4 funds opened new Avalo Therapeutics positions in Q4 2023 and 16 closed out, a net change of -12 holders.
- The largest Avalo Therapeutics buyer in Q4 2023 was BlackRock, an estimated $348K added.
- The largest Avalo Therapeutics seller in Q4 2023 was Acadian Asset Management, an estimated $34K sold.
Based on aggregated 13F filings for Q4 2023.